SOURCE: Theravance, Inc.

Theravance, Inc.

July 22, 2015 16:05 ET

Theravance to Report Second Quarter 2015 Financial Results on July 29, 2015

SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 22, 2015) - Theravance, Inc. (NASDAQ: THRX) announced today that it will report financial results for the second quarter ended June 30, 2015 after market close on Wednesday, July 29, 2015. Theravance management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.

To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.thrxinc.com and will be archived there for 30 days. A telephone replay of the call will be available by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering the confirmation code 84038673.

About Theravance

Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the agreement with GSK, Theravance is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Theravance retains a 15% economic interest in future payments made by GSK to Theravance BioPharma for earlier-stage programs. For more information, please visit Theravance's website at www.thrxinc.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(THRX-F)

Contact Information